Patent US5532278A successfully refreshed from Google Patents.
US5532278A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
Assignee: Sumitomo Pharma America Inc
•
Filing: 1995-01-31
•
Granted: 1996-07-02
•
Expires: 2015-01-31
Abstract
Abstract A method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering a therapeutically effective amount of (S)-oxybutynin or a pharmaceutically acceptable salt thereof, substantially free of its R enantiomer. Pharmaceutical compositions comprising (S)-oxybutynin and an acceptable carrier are also disclosed.
Inventors
- 👤 Gunnar Aberg
- 👤 John R. McCullough
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 19:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; A61K31/216
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
42 words
A method for treating urinary incontinence while avoiding concomitant liability of adverse effects, which comprises administering to a human in need of such treatment a therapeutically effective amount of (S)-oxybutynin or a pharmaceutically acceptable salt thereof, substantially free of its (R) enantiomer.
Claim 2
Independent Claim
42 words
A method for treating urinary incontinence while avoiding concomitant liability of adverse effects, which comprises administering to a human in need of such treatment a therapeutically effective amount of (S)-oxybutynin or a pharmaceutically acceptable salt thereof, substantially free of its (R) enantiomer.
Claim 3
Dependent Claim
19 words
The method of claim 1 wherein (S)-oxybutynin is administered by inhalation or by parenteral, transdermal, rectal or oral administration.
Claim 4
Dependent Claim
28 words
The method of claim 2 wherein the amount of (S)-oxybutynin or a pharmaceutically acceptable salt thereof administered is from about 1 mg to about 100 mg per day.
Claim 5
Dependent Claim
16 words
The method according to claim 1 wherein (S)-oxybutynin, or pharmaceutically acceptable salt thereof, is administered orally.
Claim 6
Dependent Claim
16 words
The method according to claim 1 wherein (S)-oxybutynin, or pharmaceutically acceptable salt thereof, is administered transdermally.
Claim 7
Dependent Claim
36 words
A pharmaceutical unit dosage form which comprises a therapeutically effective amount of (S)-oxybutynin, or a pharmaceutically acceptable salt thereof, substantially free of its (R) stereoisomer, and a pharmaceutically acceptable carrier in the form of a tablet.
Claim 8
Dependent Claim
36 words
A pharmaceutical unit dosage form which comprises a therapeutically effective amount of (S)-oxybutynin, or a pharmaceutically acceptable salt thereof, substantially free of its (R) stereoisomer, and a pharmaceutically acceptable carrier in the form of a tablet.
Claim 9
Dependent Claim
17 words
A pharmaceutical unit dosage form according to claim 6 comprising from 0.5 to 25 mg of (S)-oxybutynin.
Claim 10
Dependent Claim
38 words
A pharmaceutical unit dosage form which comprises a therapeutically effective amount of (S)-oxybutynin, or a pharmaceutically acceptable salt thereof, substantially free of its (R) stereoisomer, and a pharmaceutically acceptable carrier in the form of a transdermal delivery device.
Claim 11
Dependent Claim
38 words
A pharmaceutical unit dosage form which comprises a therapeutically effective amount of (S)-oxybutynin, or a pharmaceutically acceptable salt thereof, substantially free of its (R) stereoisomer, and a pharmaceutically acceptable carrier in the form of a transdermal delivery device.
Claim 12
Dependent Claim
18 words
A pharmaceutical unit dosage form according to claim 8 wherein said pharmaceutically acceptable carrier comprises a permeation enhancer.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-07-02 | 2000-01-01 | 2000-07-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-07-02 | 2004-01-01 | 2004-07-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-07-02 | 2008-01-01 | 2008-07-02 | $7700.00 | Window Closed / Lapsed |